AN
57
3
ORCL
65
7
K
39
-3
DE
32
9
NTAP
73
9
EOG
30
-2
AXP
69
2
JNPR
43
2
CSX
44
3
EQR
56
3
SPG
63
7
UA
32
-12
M
52
2
BWA
41
3
MDLZ
36
-2
BLK
61
11
LOW
42
2
MET
56
6
RL
79
4
PEG
51
5
AN
57
3
ORCL
65
7
K
39
-3
DE
32
9
NTAP
73
9
EOG
30
-2
AXP
69
2
JNPR
43
2
CSX
44
3
EQR
56
3
SPG
63
7
UA
32
-12
M
52
2
BWA
41
3
MDLZ
36
-2
BLK
61
11
LOW
42
2
MET
56
6
RL
79
4
PEG
51
5
Financhill
Back

EyePoint Pharmaceuticals 10K Form

Sell
40

EYPT
EyePoint Pharmaceuticals

Last Price:
11.14
Seasonality Move:
0.91%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive EYPT News And Ratings

See the #1 stock for the next 7 days that we like better than EYPT

EYPT Financial Statistics

Sales & Book Value

Annual Sales: $46.02M
Cash Flow: $-32.37M
Price / Cash Flow: 0
Annual Sales: $5.01
Price / Book: 2.33

Profitability

EPS (TTM): -1.81000
Net Income (TTM): $-78.92M
Gross Margin: $41.39M
Return on Equity: -55.53%
Return on Assets: -33.59%

EyePoint Pharmaceuticals Earnings Forecast

Key EyePoint Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 16 years for EYPT is 89.93%.
  • The Selling, General & Administrative Expenses for EYPT have been equal to 112.55% of Gross Profit Margin.
  • The Research & Development expenses have been 140.51% of Revenue.
  • The Interest Expense is -1.76% of Operating Income.
  • The Net Earning history of EYPT is -153.84% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 10 years.

EyePoint Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: EYPT
CUSIP: 30233G
Website: eyepointpharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.08
Quick Ratio: 4.83

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

EYPT Technical Analysis vs Fundamental Analysis

Sell
40
EyePoint Pharmaceuticals (EYPT) is a Sell

Is EyePoint Pharmaceuticals a Buy or a Sell?